SEC Form 4 · accession 0001610717-26-000362

Neumora Therapeutics, Inc. · NMRA

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Daljit Singh Aurora

Officer — See Remarks

Period of report

Aug 17, 2026

Accepted (ET)

Aug 19, 2026 · 7:17 pm EDT

Rule 10b5-1 plan

box not checked

Issuer CIK

0001885522

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock	Aug 17, 2026	M	40,890	$0.72	A	123,660	D
Common Stock	Aug 17, 2026	M	15,355	$0.72	A	139,015	D
Common Stock	Aug 17, 2026	M	1,424	$0.72	A	140,439	D
Common Stock	Aug 17, 2026	M	1	$0.72	A	140,440	D
Common Stock^F1	Aug 17, 2026	S	57,670	$1.5055	D	82,770	D
Common Stock^F2	Aug 17, 2026	S	34,020	$1.4853	D	48,750	D
Common Stock^F3	Aug 17, 2026	M	25,279	$0.72	A	25,279	I	See footnote
Common Stock^F3	Aug 17, 2026	M	29,737	$0.72	A	55,016	I	See footnote
Common Stock^F4,F3	Aug 17, 2026	S	55,016	$1.5047	D	0	I	See footnote
Common Stock	Aug 18, 2026	M	34,162	$0.72	A	82,912	D
Common Stock^F9	Aug 18, 2026	S	34,162	$1.5847	D	48,750	D
Common Stock^F3	Aug 18, 2026	M	34,987	$0.72	A	34,987	I	See footnote
Common Stock^F10,F3	Aug 18, 2026	S	34,987	$1.5859	D	0	I	See footnote
Common Stock	Aug 19, 2026	M	13,268	$0.72	A	62,018	D
Common Stock	Aug 19, 2026	M	17,732	$0.72	A	79,750	D
Common Stock^F11	Aug 19, 2026	S	31,000	$1.6461	D	48,750	D
Common Stock^F3	Aug 19, 2026	M	30,918	$0.72	A	30,918	I	See footnote
Common Stock^F12,F3	Aug 19, 2026	S	30,918	$1.6459	D	0	I	See footnote

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (Right to Buy)^F5	$0.72	Aug 17, 2026	M	40,890	D	—	Sep 20, 2031	Common Stock	40,890	0	D
Stock Option (Right to Buy)^F6	$0.72	Aug 17, 2026	M	15,355	D	—	Jan 19, 2033	Common Stock	15,355	192,546	D
Stock Option (Right to Buy)^F7	$0.72	Aug 17, 2026	M	1,424	D	—	Jun 23, 2033	Common Stock	1,424	70,797	D
Stock Option (Right to Buy)^F8	$0.72	Aug 17, 2026	M	1	D	—	Feb 13, 2035	Common Stock	1	999,999	D
Stock Option (Right to Buy)^F3,F5	$0.72	Aug 17, 2026	M	25,279	D	—	Jan 19, 2033	Common Stock	25,279	110,931	I
Stock Option (Right to Buy)^F3,F5	$0.72	Aug 17, 2026	M	29,737	D	—	Jun 23, 2033	Common Stock	29,737	0	I
Stock Option (Right to Buy)^F7	$0.72	Aug 18, 2026	M	34,162	D	—	Jun 23, 2033	Common Stock	34,162	36,635	D
Stock Option (Right to Buy)^F3,F5	$0.72	Aug 18, 2026	M	34,987	D	—	Jan 19, 2033	Common Stock	34,987	75,944	I
Stock Option (Right to Buy)^F7	$0.72	Aug 19, 2026	M	13,268	D	—	Jun 23, 2033	Common Stock	13,268	23,367	D
Stock Option (Right to Buy)^F13	$0.72	Aug 19, 2026	M	17,732	D	—	Feb 14, 2034	Common Stock	17,732	177,268	D
Stock Option (Right to Buy)^F3,F5	$0.72	Aug 19, 2026	M	30,918	D	—	Jan 19, 2033	Common Stock	30,918	45,026	I

Explanation of responses

F1This transaction was executed in multiple trades at prices ranging from $1.46 to $1.555, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F10This transaction was executed in multiple trades at prices ranging from $1.48 to $1.65, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F11This transaction was executed in multiple trades at prices ranging from $1.62 to $1.6995, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F12This transaction was executed in multiple trades at prices ranging from $1.62 to $1.7006, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F1325% of the shares subject to the option vest on the first anniversary measured from February 14, 2024 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
F2This transaction was executed in multiple trades at prices ranging from $1.46 to $1.5277, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F3Shares held by Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries.
F4This transaction was executed in multiple trades at prices ranging from $1.46 to $1.555, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F5The stock option is fully vested and exercisable.
F625% of the shares subject to the option vest on the first anniversary measured from February 1, 2023 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
F725% of the shares subject to the option vest on the first anniversary measured from June 30, 2023 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
F825% of the shares subject to the option vest on the first anniversary measured from February 13, 2025 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
F9This transaction was executed in multiple trades at prices ranging from $1.49 to $1.645, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Remarks

Title: Chief Operating and Development Officer